Justine Anastasia Barletta, M.D.
This page shows the publications co-authored by Justine Barletta and Lynette Sholl.
Sholl LM, Barletta JA, Hornick JL. Radiation-associated neoplasia: clinical, pathological and genomic correlates. Histopathology. 2017 Jan; 70(1):70-80.
Howitt BE, Jia Y, Sholl LM, Barletta JA. Molecular alterations in partially-encapsulated or well-circumscribed follicular variant of papillary thyroid carcinoma. Thyroid. 2013 Oct; 23(10):1256-62.
Sholl LM, Barletta JA, Yeap BY, Chirieac LR, Hornick JL. Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma. Am J Surg Pathol. 2010 Aug; 34(8):1193-8.
Rabinowits G, Barletta J, Sholl LM, Reche E, Lorch J, Goguen L. Successful Management of a Patient with Malignant Thyroid Teratoma. Thyroid. 2017 01; 27(1):125-128.
Mirkovic J, Sholl LM, Garcia E, Lindeman N, MacConaill L, Hirsch M, Dal Cin P, Gorman M, Barletta JA, Nucci MR, McCluggage WG, Howitt BE. Targeted genomic profiling reveals recurrent KRAS mutations and gain of chromosome 1q in mesonephric carcinomas of the female genital tract. Mod Pathol. 2015 Nov; 28(11):1504-14.
Adackapara CA, Sholl LM, Barletta JA, Hornick JL. Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma. Histopathology. 2013 Aug; 63(2):187-93.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.